Recent applications of phosphodiesterase (PDE5) inhibition assays for detecting adulterated sexual enhancement products

Consumer products marketed for sexual enhancement are frequently adulterated with erectile dysfunction (ED) drugs and analogs; consuming these undisclosed adulterants can pose significant health hazards. Although ED drugs/analogs have unpredictable and diverse structures that pose challenges for det...

Full description

Saved in:
Bibliographic Details
Published in:Drug testing and analysis 2022-04, Vol.14 (4), p.757-761
Main Author: Santillo, Michael F.
Format: Article
Language:English
Subjects:
Drug therapy
Erectile dysfunction
Erectile Dysfunction - drug therapy
Humans
Male
Phosphodiesterase 5 Inhibitors - pharmacology
Phosphoric Diester Hydrolases
Sexual disorders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Consumer products marketed for sexual enhancement are frequently adulterated with erectile dysfunction (ED) drugs and analogs; consuming these undisclosed adulterants can pose significant health hazards. Although ED drugs/analogs have unpredictable and diverse structures that pose challenges for detecting them, they all share the ability to inhibit phosphodiesterase‐5 (PDE5) activity, a pharmacological mechanism responsible for their effects. Consequently, several PDE5 inhibition assays have been recently applied as screening methods to detect ED drug/analogs in products. Here, the successes and challenges are highlighted for screening sexual enhancement products by PDE5 inhibition assays.
ISSN:1942-7603
1942-7611
DOI:10.1002/dta.3209